



We expand, promote, facilitate multidisciplinary activities in HIV/AIDS research!

[HU CFAR HOME](#) | [CORE SERVICES](#) | [RESEARCH PRIORITIES](#)

IN THIS NEWSLETTER:

Spotlight

Opportunities / Events

HU CFAR Series

Publications Highlights

Current Funding Opportunities

Acknowledgments

SPOTLIGHT

The HU CFAR Advanced Lab Technologies (ALT) Core



Whom does the ALTC serve and how?

The ALTC serves hundreds of HU CFAR users and their global collaborators. The ALTC also continues to focus on providing critical technical support to Early Stage Investigators (ESI), including over a dozen Developmental & Mentoring Core awardees. The overall mission of the ALTC is to provide access to advanced cytometric/microscopic/genomic technologies that may otherwise be cost-prohibitive or inaccessible.

Does the ALTC support user training?

Yes. The core aims to provide user training in all ALTC technologies, as well as computational assistance. We offer training and daily consultation to support the immediate use of new instrumentation. Experiments include: multiparameter flow cytometric evaluation of cultured cells, peripheral blood, and tissue specimens including high-throughput BSL2 cell sorting and access to BSL2+ and BSL3 sorting; high resolution imaging of BSL2+ and BSL3 samples; and high throughput genomic sequencing and single cell analyses.

Does the BSL3 also support COVID-19 related research?

Yes. The BSL3 offers support for experimental cell culture and virologic work with SARS-CoV-2, including consultation for experimental planning, technical execution of experiments, access to biosafety facilities with the capacity for SARS-CoV-2 work, and didactic and hands-on training in the safe use of those facilities. The BSL3 also offers access to several SARS-CoV-2 reagents, including a bank of sequenced clinical isolates reflecting variants currently in circulation.

Where is the ALTC and how do I access it?

The ALTC can be contacted at each of its three sites: Beth Israel Deaconess Medical Center (flow cytometry, custom cytometric reagents, BL2+ sorting); The Ragon Institute of MGH, MIT and Harvard (BSL2+, and BSL3 flow cytometry, sorting and imaging); and the Dana-Farber Cancer Institute (Next-Generation Sequencing, sample library preparation, and analysis). All of these services are integrated so that samples and projects can easily move between sites.

[Visit the ALT Core!](#)

OPPORTUNITIES / EVENTS

HU CFAR RFPs for February 2022 Developmental Awards

The Harvard University Center for AIDS Research is pleased to announce a **Request for Proposals in HIV/AIDS research for Early Career Investigators**. Awards beginning on or after February 1, 2022.



APPLY HERE by NOVEMBER 17 (4 PM ET), 2021!

PROPOSALS FOR RESEARCH IN ALL HIV-RELATED DISCIPLINES ARE INVITED!

HU CFAR Grand Rounds Webinar Series

The **virtual HU CFAR Grand Rounds webinar series** is an opportunity for Harvard-affiliated HIV researchers and their collaborators to present high impact, cutting-edge research to the HU CFAR community. If you're interested in presenting at a future webinar, suggest a topic, or learn more about it, please contact Mark Ingaciola at mark_ingaciola@harvard.edu.



Watch past HU CFAR Grand Rounds webinars!

HIV Working Group | October 8 (1 - 1:50pm ET)

Department of Biostatistics | Harvard T.H. Chan School of Public Health

Causal organic indirect and direct effects: closer to Baron and Kenny, with a product method for binary mediators

Join the October 8 HIV Working Group session! Password: 722888

See the HIV Working Group series' upcoming dates and speakers!

HGHI Leadership is offering a new Gen Ed Course on Vaccines

HGHI Interim Faculty Director Dr. Allan Brandt and HGHI Associate Faculty Director Dr. Ingrid Katz joined HU CFAR Co-Director Dr. Galit Alter to offer a new Gen Ed course this fall, **Vaccines: History, Science, Policy (Gen Ed 1175)**. The course takes a deep dive into the history, science, and policy issues that have defined this public health tool.



The CFAR at Emory University is now accepting applications

4th annual Planning for Success (Pfs) NIH R-level Grant Writing course.

Are you interested in building a career as an NIH-funded HIV researcher? Would you like to learn how to write an NIH HIV-related R-level grant while drafting one for submission?

APPLY HERE by OCTOBER 18, 2021! (Eligibility includes individuals who have not yet submitted their first R-level application and individuals whose previous R-level submission(s) to NIH have been unsuccessful.) **Harvard-affiliated investigators are welcome to apply!**

For questions about the program, please contact Galina Terbova galina.terbova@emory.edu

Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Vaccine Workshop



The Office of HIV and AIDS Malignancy (OHAM) in the National Cancer Institute is hosting a virtual workshop on **Wednesday, October 13, 2021 from 10 AM-5:30 PM EST** to discuss the need, potential, and feasibility of developing a vaccine against Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8). The focus of the workshop will be on vaccines to prevent initial infection or prevent the development of disease, **NOT** on a therapeutic vaccine. [View the KSHV Vaccine Workshop draft agenda!](#)

The WebEx link <https://cbit.webex.com/cbit/j.php?MTID=m64431d859831e3af8002eca5d56140e4>

Event number: **2302 823 8380**

Event password: **ZMqc32GsP@7 (96723247 from phones)**

Join by phone: **1-650-479-3207** Call-in toll number (US/Canada)

Access code: **230 282 38380**

Miami CFAR Seminar
October 5, 2021 (12 PM ET)



Managing HIV Patients with Limited Treatment Options

Dr. Michael Kozal, Stanford University

Dr. Dushyantha Jayaweera, Miami Miller School of Medicine

[Register to attend and receive the Miami CFAR seminar link !](#)

UJMT Fogarty Global Health Fellowship 2022 Call for Applications



The UJMT Consortium is **accepting applications for 2022-2023** for the NIH Fogarty Global Health Fellows & Scholars Program. Submission deadline November 1, 2021.

[Learn about the UJMT Fogarty Global Health fellowship!](#)

October 2021 Virtual AIDS Clinical Conference
Tuesday, 10/19/21 (8-9 AM Pacific)



Revisiting the Invisible Latino HIV Crisis - Examining Progress and Identifying Remaining Gaps in the National Response

[Register to the AIDS clinical conference!](#)

HU CFAR SERIES

First Wednesdays: Research in Development | October 6, 2021 (4-5pm ET)

R34 Submission: Provider-Level Substance Use and HIV Stigma Reduction Intervention Development and Pilot

HIV Research in Progress | October 8, 2021 (8-9am ET)

Developing an Integrative, Comprehensive Cardiovascular Disease Risk Reduction Intervention for People With HIV

HIV Online Provider Education (HOPE) | Physicians and Nurses conferences

SAVE THE DATE!

HU CFAR GRAND ROUNDS WEBINAR | November 10, 2021 (2pm EST/11am PST)

Topic: *Advances in Monitoring and Promoting PrEP Adherence*

PUBLICATIONS HIGHLIGHTS

Antigen Presenting Cells Link the Female Genital Tract Microbiome to Mucosal Inflammation, With Hormonal Contraception as an Additional Modulator of Inflammatory Signatures



Case 27-2021: A 16-Year-Old Boy Seeking Human Immunodeficiency Virus Prophylaxis

Functional impairment of HIV-specific T cells precedes aborted virus control

CURRENT FUNDING OPPORTUNITIES

HU CFAR RFP for Developmental Awards

The Harvard University Center for AIDS Research is pleased to announce a **Request for Proposals in HIV/AIDS research for Early Career Investigators**. Awards beginning on or after February 1, 2022.

NIH Funding Opportunities

The Emerging Global Leader Award (K43) have been reissued. The Emerging Global Leader Award is a global health research career development award for LMIC early career researchers based at LMIC institutions. Please share these funding opportunities with your networks:

- **Emerging Global Leader Award (K43 Independent Clinical Trial Required) - PAR-21-251**
- **Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed) - PAR-21-252**

The **Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC)** program supports individual postdoctoral career transition awards and institutionally-focused research education cooperative agreements:

- **MOSAIC Program Funding Opportunities Promote Diversity**

Be AWARE of New Initiative To Study HIV Prevention in Women

Are you capable of positively impacting the HIV epidemic among women living in the United States? Do you have novel ideas about how to use digital technology to reach women, gather insights through epidemiologic methods, and harness data science approaches to better understand HIV prevention, transmission, and early care-cascade points focused on women? If so, apply for research project funding through the:

- **American Women: Assessing Risk Epidemiologically (AWARE) (R01, Clinical Trial Optional).**

Funding Opportunity To Detect and Report HIV-1 Drug Resistance Mutations

If you have the expertise to develop or optimize next-generation methodologies to detect HIV-1 drug resistance (DR) mutations and rapidly disseminate the information, consider applying for a grant through the:

- **Notice of Special Interest (NOSI): HIV DR Assays and Actionable Data Dissemination Strategies.**

[VIEW MORE FUNDING HERE!](#)

ACKNOWLEDGEMENTS

This newsletter is a publication of the **[Harvard University Center for AIDS Research \(HU CFAR\), an NIH funded program \(P30 AI060354\)](#)** which is supported by the following NIH Co-Funding and Participating Institutes and Centers: NIAID, NCI, NICHD, NIDCR, NHLBI, NIDA, NIMH, NIA, NIDDK, NINR, NIMHD, FIC, and OAR. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

To learn more about core services available to the Harvard HIV research community and for information about the HU CFAR, please visit <https://cfar.globalhealth.harvard.edu/>

[Click here to view past newsletters!](#)



Harvard University Center for AIDS Research